Tender for Suministro de Medicamentos Exclusivos con Principios activos Bimekizumab, Fenfluramina, Inebilizumab, Lumasiran, Mirikizumab, Pitolisant, Tafasitamab, Tensioactivo Pulmonar Porcino, Tuberculina, Velmanasa y Vutrisiran de los laboratorios farmacéuticos Alnylam Pharmaceuticals Spain, S.L., Amgen, S.A., Biomarin Pharmaceuticals España, S. L., Chiesi España, S.A.U., Incyte Biosciences Iberia, S.L., Li

The tender identified with expedient CS/9999/1101155528/24/EXCL is related to the sector Supplies. This tender, published on September 24, 2025 and last updated on September 24, 2025, aims to Medicamentos Exclusivos con Principios activos Bimekizumab, Fenfluramina, Inebilizumab, Lumasiran, Mirikizumab, Pitolisant, Tafasitamab, Tensioactivo Pulmonar Porcino, Tuberculina, Velmanasa y Vutrisiran. The estimated value of the contract is €28,416,085.20 , with a budget excluding taxes of €10,524,476.00 . The procedure modality is Negociado sin publicidad, and currently its status is Adjudicada.

This tender is located in Murcia, ES, Región de Murcia, ES. The main source of this information is Plataforma de Contratación del Sector Público .

The tender is classified under several CPV codes, including CPV, among others Diagnostic agents (No code: 33694000), Medicinal products for the respiratory system (No code: 33670000), among others.